135 related articles for article (PubMed ID: 38057916)
1. Correction: Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC).
Lee SY; Cho HJ; Choi J; Ku B; Moon SW; Moon MH; Kim KS; Hyun K; Kim TJ; Sung YE; Hwang Y; Lee E; Ahn DH; Choi JY; Lim JU; Park CK; Kim SW; Kim SJ; Koo IS; Jung WS; Lee SH; Yeo CD; Lee DW
J Exp Clin Cancer Res; 2023 Dec; 42(1):332. PubMed ID: 38057916
[No Abstract] [Full Text] [Related]
2. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC).
Lee SY; Cho HJ; Choi J; Ku B; Moon SW; Moon MH; Kim KS; Hyun K; Kim TJ; Sung YE; Hwang Y; Lee E; Ahn DH; Choi JY; Lim JU; Park CK; Kim SW; Kim SJ; Koo IS; Jung WS; Lee SH; Yeo CD; Lee DW
J Exp Clin Cancer Res; 2023 Nov; 42(1):309. PubMed ID: 37993887
[TBL] [Abstract][Full Text] [Related]
3. Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement.
Fujiwara A; Higashiyama M; Kanou T; Tokunaga T; Okami J; Kodama K; Nishino K; Tomita Y; Okamoto I
Lung Cancer; 2014 Feb; 83(2):302-4. PubMed ID: 24360322
[TBL] [Abstract][Full Text] [Related]
4. Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer.
Iwama E; Okamoto I; Harada T; Takayama K; Nakanishi Y
Onco Targets Ther; 2014; 7():375-85. PubMed ID: 24623980
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and computed tomography features of patients with early-stage non-small-cell lung cancer harboring ALK rearrangement.
Hou X; Chen H; Liu Y; Gong S; Zhudai M; Shen L
Cancer Imaging; 2023 Feb; 23(1):20. PubMed ID: 36823653
[TBL] [Abstract][Full Text] [Related]
6. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR-negative lung cancer.
Mori M; Hayashi H; Fukuda M; Honda S; Kitazaki T; Shigematsu K; Matsuyama N; Otsubo M; Nagayasu T; Hashisako M; Tabata K; Uetani M; Ashizawa K
Thorac Cancer; 2019 Apr; 10(4):872-879. PubMed ID: 30811109
[TBL] [Abstract][Full Text] [Related]
7. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
[TBL] [Abstract][Full Text] [Related]
8. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing.
V Laffert M; Warth A; Penzel R; Schirmacher P; Jonigk D; Kreipe H; Schildhaus HU; Merkelbach-Bruse S; Büttner R; Reu S; Kerler R; Jung A; Kirchner T; Wölfel C; Petersen I; Rodriguez R; Jochum W; Bartsch H; Fisseler-Eckhoff A; Berg E; Lenze D; Dietel M; Hummel M
Lung Cancer; 2013 Aug; 81(2):200-6. PubMed ID: 23669200
[TBL] [Abstract][Full Text] [Related]
10. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
[TBL] [Abstract][Full Text] [Related]
13. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
[TBL] [Abstract][Full Text] [Related]
14. [Identification of an optimal algorithm for effective diagnostics of non-small cell lung cancer with ALK gene rearrangement - implementation of the method and practical experiences with routine diagnostics].
Rozkoš T; Ryška A; Nová M; Hornychová H; Krbal L; Matěj R; Laco J
Cesk Patol; 2017; 53(2):89-96. PubMed ID: 28597670
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
16. CT Characteristics of Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangement: A Systematic Review and Meta-Analysis.
Kim TH; Woo S; Yoon SH; Halpenny DF; Han S; Suh CH
AJR Am J Roentgenol; 2019 Nov; 213(5):1059-1072. PubMed ID: 31414902
[No Abstract] [Full Text] [Related]
17. Clinical value of serum albumin level in patients with non-small cell lung cancer and anaplastic lymphoma kinase (ALK) rearrangement.
Zhang X; Xing P; Hao X; Li J
Ann Palliat Med; 2021 Dec; 10(12):12403-12411. PubMed ID: 35016425
[TBL] [Abstract][Full Text] [Related]
18. Ventana immunohistochemistry assay for anaplastic lymphoma kinase gene rearrangement detection in patients with non-small cell lung cancer: A meta-analysis.
Zhiwei W; Yuan J; Yihui Y; Xin H; Jingtao C; Lei S; Yongjian D
Thorac Cancer; 2017 Sep; 8(5):471-476. PubMed ID: 28742247
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies between ALK protein disruption and occurrence of
Grenda A; Jarosz B; Krawczyk P; Kucharczyk T; Wojas-Krawczyk K; Reszka K; Krukowska K; Nicoś M; Pankowski J; Bryl M; Ramlau R; Kuźnar-Kamińska B; Grodzki T; Szczęsna A; Siemiątkowska K; Szumiło J; Batura-Gabryel H; Palonka M; Milanowski J
J Thorac Dis; 2018 Aug; 10(8):4994-5009. PubMed ID: 30233874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
